Does Cigna Cover Wegovy in 2026?

Yes on plans that include weight-loss benefits, with prior authorization — and Cigna's bar is materially lower than Aetna's. Where Aetna wants six months of documented weight-management programme participation before the prescription, Cigna asks for three. Where Aetna names three example comorbidities at BMI 27, Cigna lists eleven.

That gap is the single most useful thing on this page. If an Aetna denial is what brought you here, or you are choosing between plans at open enrolment, the same body can qualify under one and not the other. We archived Cigna's policy cnf_684 on July 25, 2026; everything below quotes it.

Does Cigna cover Wegovy?

Yes, with prior authorization, on plans whose benefit includes weight-loss drugs. Cigna's national formulary policy cnf_684 covers Wegovy injection, Wegovy HD injection and the Wegovy tablet by name. The qualifier matters more than the answer: a separate Cigna policy variant exists for plans that exclude the class outright, and on those no criteria apply because there is no benefit to apply them to.

Worth knowing before you read further: Cigna dropped GLP-1 obesity coverage for its own employees, as Reuters reported. That tells you nothing about your plan, but it is a useful reminder that the insurer administering your benefit and the employer buying it make separate decisions.

Three months, not six: the trial that decides it

Prior authorization is Cigna's pre-approval step: your prescriber documents that you meet the policy criteria before the pharmacy can fill. The criterion people fail is the trial requirement, and Cigna's is half the length of Aetna's.

Four conditions must all hold for initial approval: you are 18 or older, you have completed that three-month trial, you clear one of the two BMI doors below, and the medication will be used alongside behavioural modification and a reduced-calorie diet. There is a separate pathway for patients from age 12 at or above the 95th BMI percentile.

Eleven conditions at BMI 27, not three

The BMI doors are the familiar pair: 30 or higher on its own, or 27 or higher with a weight-related comorbidity. What is unusual is how long Cigna's comorbidity list runs.

All eleven, verbatim: hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease, knee osteoarthritis, asthma, chronic obstructive pulmonary disease, metabolic dysfunction-associated steatotic liver disease / non-alcoholic fatty liver disease, polycystic ovarian syndrome, or coronary artery disease.

Compare that with the three Aetna offers as examples in its own Wegovy policies: hypertension, type 2 diabetes, dyslipidemia. Sleep apnea, PCOS, asthma, knee osteoarthritis and fatty liver disease all qualify you at Cigna and are absent from Aetna's list. If you were turned down at BMI 27 elsewhere, this is the paragraph to bring to your prescriber.

One more clause that quietly helps switchers: the policy states baseline BMI refers to the point before any GLP-1 or GIP agonist. Losing weight on Zepbound or Saxenda does not disqualify you from Wegovy. Bring the chart note showing your starting number.

Eight months, then a year

Initial approval runs 8 months. Continuation, once you are established on Wegovy injection, Wegovy HD or the tablet, is approved for 1 year at a time.

That eight-month first window is longer than Cigna gives liraglutide, which the same policy caps at four. The practical consequence is the same either way: have your weight recorded in the chart at every visit from the first fill, because renewal turns on documented loss and a home scale is not documentation.

When the plan excludes the drug class outright

Cigna publishes a benefit-exclusion variant of this policy, and it ranks on this very search. If your employer bought that design, Wegovy is not a covered benefit at all, criteria are irrelevant, and a prior authorization cannot succeed. Search your Summary Plan Description for "weight loss" and "anti-obesity" — exclusion language lives under those exact phrases.

Why did Cigna deny my Wegovy?

Either the documentation missed a criterion, or your plan excludes the class. The denial letter says which, and the two have completely different fixes.

For a criteria denial, the usual gaps are the three-month trial with dates, the baseline BMI chart note from before any GLP-1, and the comorbidity diagnosis in the record rather than mentioned in passing. File the internal appeal with the specific missing document attached; resubmitting the same packet achieves nothing. If the internal appeal fails, external review by an independent physician is your right in every state.

For a benefit exclusion, appeals almost never succeed. The realistic routes are a formulary exception request arguing medical necessity, a different covered indication if one genuinely applies, or paying cash while you sort it out.

What it costs, and the $200 cap your employer may have taken

Covered, you pay your plan's tier copay. There is also a benefit-design option worth asking HR about: Evernorth, Cigna's pharmacy benefit manager, announced in May 2025 a plan-sponsor option capping employee copays for Wegovy and Zepbound at $200 a month. Two caveats we will not paper over — it is an option employers elect rather than a universal Cigna benefit, and we could not confirm it on Cigna's own site, only in secondary coverage. Treat it as a question for your benefits team, not a promise.

The manufacturer savings offer that brings some people to $25 a month requires commercial insurance that already covers the drug, and excludes Medicare, Medicaid and TRICARE by its own terms. If you are uncovered, the honest comparison is between cash-pay programs, and the figure that decides it is the membership fee rather than the advertised headline. Our cost calculator adds those back in.

How to check your own plan

1. Search your plan documents for "weight loss" and "anti-obesity" before anything else. This tells you whether you are in the criteria conversation at all.
2. Confirm which policy variant applies — the prior-authorization version (cnf_684) or the benefit-exclusion version. Member services can answer this in one call.
3. Line up the three documents your prescriber will need: dated records of the three-month trial, the baseline BMI note from before any GLP-1, and the comorbidity diagnosis.

If step one turns up an exclusion, stop there and price the cash route instead of spending weeks on a request that cannot be approved. Compare verified programs. How we make money.

FAQ

How long does Cigna approve Wegovy for?

Eight months on initial approval, then one year at a time for continuation once you are established on Wegovy injection, Wegovy HD or the tablet.

Does Cigna cover the Wegovy tablet?

Policy cnf_684 names Wegovy tablet alongside the injection and Wegovy HD, so the oral form sits under the same criteria. That is ahead of several other insurers, whose published policies still describe pens only.

Does Cigna cover Wegovy for sleep apnea?

Obstructive sleep apnea is one of the eleven comorbidities that qualify you at BMI 27 or higher, so it opens the standard weight-management pathway rather than a separate one.

Will losing weight on another GLP-1 disqualify me?

No. The policy measures baseline BMI from before any GLP-1 or GIP agonist, so a documented starting number carries across a switch.

What if my Cigna plan excludes weight-loss drugs?

Then no prior authorization can succeed. Your options are a formulary exception request, a different covered indication if one genuinely applies, or paying cash.

Sources and update history

Primary document, archived July 25, 2026: Cigna National Formulary coverage policy cnf_684, Weight Loss — GLP-1 Agonists Prior Authorization (reviewed 2025-07-09; revised through 2026-04-15). The $200 copay option is reported in secondary coverage dated May 28, 2025 and is not confirmed on Cigna's own site. Companion pages: Aetna and Wegovy, Cigna and Zepbound.